Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Biodistribution of DaTscan in Chinese Healthy Volunteers
NCT04564092Phase 1Completed
- Sponsor
- GE HealthCare
- Start
- May 2021
- Primary completion
- Sep 2021
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ioflupane I-123 in Parkinson's disease (PD), sponsored by GE HealthCare. Primary endpoints: Number of Participants With Adverse Events at 2 weeks, Change From Baseline in Tolerability Questionnaire Score at 48 hours and 9 more. Started May 2021; status: completed.
02
Drugs
ioflupane I-123
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04564092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04564092.